이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genscript Biotech 과거 수익 실적

과거 기준 확인 0/6

Genscript Biotech의 수입은 연평균 -23.2%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 22.4%의 비율로 증가했습니다. 매출은 연평균 25.7%의 비율로 증가해 왔습니다.

주요 정보

-23.2%

수익 성장률

-21.2%

EPS 성장률

Life Sciences 산업 성장	41.4%
매출 성장률	25.7%
자기자본 수익률	-17.4%
순이익	-11.4%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Genscript Biotech 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SHSC:1548 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	840	-95	393	433
30 Sep 23	773	-140	383	426
30 Jun 23	707	-185	374	420
31 Mar 23	667	-206	363	405
31 Dec 22	626	-227	352	390
30 Sep 22	598	-315	354	375
30 Jun 22	570	-403	356	361
31 Mar 22	530	-381	330	360
31 Dec 21	490	-359	303	358
30 Sep 21	483	-265	270	341
30 Jun 21	454	-183	235	323
31 Mar 21	422	-194	216	293
31 Dec 20	391	-205	197	263
30 Sep 20	354	-194	171	251
30 Jun 20	318	-183	146	239
31 Mar 20	296	-140	136	212
31 Dec 19	273	-97	126	186
30 Sep 19	257	-59	112	148
30 Jun 19	241	-22	98	109
31 Mar 19	236	0	89	92
31 Dec 18	231	21	79	74
30 Sep 18	216	24	72	58
30 Jun 18	201	27	65	41
31 Mar 18	177	26	56	30
31 Dec 17	153	26	47	18
30 Sep 17	139	27	48	11
30 Jun 17	125	28	49	5
31 Mar 17	120	27	50	2
31 Dec 16	115	26	51	0
30 Sep 16	107	26	50	0
30 Jun 16	99	25	48	0
31 Mar 16	93	21	47	0
31 Dec 15	87	18	46	0
30 Sep 15	82	13	43	0
30 Jun 15	78	8	39	0
31 Mar 15	74	7	38	0
31 Dec 14	70	6	37	0
31 Dec 13	60	6	29	0

양질의 수익: 1548 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 1548 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 1548 은(는) 수익성이 없으며 지난 5년 동안 연간 23.2% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 1548 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 1548 은(는) 수익성이 없어 지난 해 수익 성장을 Life Sciences 업계( 0.7% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 1548 현재 수익성이 없기 때문에 마이너스 자본 수익률( -17.37% )을 갖습니다.

Genscript Biotech 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Recent updates

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기